Die gastroösophageale Refluxkrankheit in der Schwangerschaft

• Literatur

• 1 Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013; 108: 308-328
• 2 Koop H, Fuchs KH, Labenz J et al. S2k-Leitlinie: Gastroösophageale Refluxkrankheit. Z Gastroenterol 2014; 52: 1299-1346
• 3 Vakil N, van Zanten SV, Kahrilas P et al. Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-1920
• 4 Fill S, Malfertheiner M, Costa SD et al. [Handling of the gastroesophageal reflux disease (GERD) during pregnancy—a review]. Z Geburtshilfe Neonatol 2007; 211: 215-223
• 5 Fill Malfertheiner S, Malfertheiner MV, Monkemuller K et al. Gastroesophageal reflux disease and management in advanced pregnancy: a prospective survey. Digestion 2009; 79: 115-120
• 6 Richter JE. Review article: the management of heartburn in pregnancy. Aliment Pharmacol Ther 2005; 22: 749-757
• 7 Ronkainen J, Aro P, Storskrubb T et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol 2005; 40: 275-285
• 8 Fass R, Quan SF, OʼConnor GT et al. Predictors of heartburn during sleep in a large prospective cohort study. Chest 2005; 127: 1658-1666
• 9 Kulig M, Nocon M, Vieth M et al. Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study. J Clin Epidemiol 2004; 57: 580-589
• 10 Fass R, Achem SR. Noncardiac chest pain: epidemiology, natural course and pathogenesis. J Neurogastroenterol Motil 2011; 17: 110-123
• 11 Zagari RM, Fuccio L, Wallander MA et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrettʼs oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008; 57: 1354-1359
• 12 Fill Malfertheiner S, Malfertheiner MV, Kropf S et al. A prospective longitudinal cohort study: evolution of GERD symptoms during the course of pregnancy. BMC Gastroenterol 2012; 12: 131
• 13 Van Thiel DH, Wald A. Evidence refuting a role for increased abdominal pressure in the pathogenesis of the heartburn associated with pregnancy. Am J Obstet Gynecol 1981; 140: 420-422
• 14 Alvarez-Sanches A, Rey E, Achem SR et al. Does progesterone fluctuation across the menstrual cycle predispose to gastrooesophageal reflux?. Am J Gastroenterol 1999; 94: 1468-1471
• 15 Schade RR, Pelekans MJ, Tauxe WN et al. Gastric emptying during pregnancy. Gastroenterology 1984; 86: 1234A
• 16 Capell MS. The safety and efficacy of gastrointestinal endoscopy during pregnancy. Gastroenterol Clin North Am 1998; 27: 37-71
• 17 Malfertheiner M, Malfertheiner P, Costa SD et al. Extraesophageal symptoms of gastroesophageal reflux disease during pregnancy. Z Gastroenterol 2015; [accepted for publication]
• 18 Larson JD, Patatanian E, Miner PB et al. Double-blind, placebo-controlled study of ranitidine for gastroesophageal reflux symptoms during pregnancy. Obstet Gynecol 1997; 90: 83-87
• 19 Tytgat GN, Heading RC, Muller-Lissner S et al. Contemporary understanding and management of reflux and constipation in the general population and pregnancy: a consensus meeting. Aliment Pharmacol Ther 2003; 18: 291-301
• 20 Lindow SW, Regnell P, Sykes J et al. An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (Gaviscon Advance) in the treatment of heartburn during pregnancy. Int J Clin Pract 2003; 57: 175-179
• 21 Briggs GG, Freeman RY, Yaffe SJ. Drugs in Pregnancy and Lactation: a Reference Guide to fetal and neonatal Risk. Baltimore, USA: William and Wilkins; 2002
• 22 Finkelstein W, Isselbacker KJ. Cimetidine. N Engl J Med 1978; 229: 992-996
• 23 Magee LA, Inocencian G, Kamboijt R et al. Safety of first trimester exposure to histamine H2 blockers. A prospective cohort study. Dig Dis Sci 1996; 41: 1145-1149
• 24 Gill SK, OʼBrien L, Einarson TR et al. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol 2009; 104: 1541-1545
• 25 Nikfar S, Abdollahi M, Moretti ME et al. Use of proton pump inhibitors during pregnancy and rates of major malformations. A meta-analysis. Dig Dis Sci 2002; 47: 1526-1529
• 26 Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med 2010; 363: 2114-2123
• 27 Majithia R, David A. Are proton pump inhibitors safe during pregnancy and lactation? Evidence to Date. Drugs 2012; 72: 171-179
• 28 Matok I, Levy A, Wiznitzer A et al. The safety of fetal exposure to proton-pump inhibitors during pregnancy. Dig Dis Sci 2012; 57: 699-705
• 29 Anonymous Prevacid (product information). Lake Forest, IL, USA: TAP Pharmaceutical; 2005
• 30 Mitchell AA. Proton-pump inhibitors and birth defects – some reassurance, but more needed. N Engl J Med 2010; 363: 2161-2163
• 31 Rey E, Rodriguez-Artalejo F, Herraiz MA et al. Gastroesophageal reflux symptoms during and after pregnancy: a longitudinal study. Am J Gastroenterol 2007; 102: 2395-2400